GiACTA (GCA)

Full Name: A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis
Study Dates: 2013-2018
NCT #: NCT01791153
Study Findings: This study demonstrated that weekly tocilizumab (Actemra®) treatment, initially in combination with a six-month steroid (glucocorticoid) taper, enabled significantly more patients with GCA to achieve sustained disease remission while also significantly reducing steroid exposure compared with taking steroids alone.